Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after...

por Castro, Januario E., Lengerke-Diaz, Paula A., Velez Lujan, Juliana, Choi, Michael Y., Moreno-Cortes, Eider F., Forero, Jose V., Garcia-Robledo, Juan Esteban, Jacobs, Chaja, McCarthy, Colin, Heinen, Alaina, Amaya-Chanaga, Carlos I., Kipps, Thomas J.
Publicado 2022

Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry

por Mato, Anthony R., Barrientos, Jacqueline C., Ghosh, Nilanjan, Pagel, John M., Brander, Danielle M., Gutierrez, Meghan, Kadish, Karen, Tomlinson, Brian, Iyengar, Reethi, Ipe, David, Upasani, Sandhya, Amaya-Chanaga, Carlos I., Sundaram, Murali, Han, Jennifer, Giafis, Nick, Sharman, Jeff P.
Publicado 2019

Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathwa...

por Kashyap, Manoj K., Kumar, Deepak, Jones, Harrison, Amaya-Chanaga, Carlos I., Choi, Michael Y., Melo-Cardenas, Johanna, Ale-Ali, Amine, Kuhne, Michelle R., Sabbatini, Peter, Cohen, Lewis J., Shelat, Suresh G., Rassenti, Laura Z., Kipps, Thomas J., Cardarelli, Pina M., Castro, Januario E.
Publicado 2015

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia

por Kashyap, Manoj K., Amaya-Chanaga, Carlos I., Kumar, Deepak, Simmons, Brett, Huser, Nanni, Gu, Yin, Hallin, Max, Lindquist, Kevin, Yafawi, Rolla, Choi, Michael Y., Amine, Ale-Ali, Rassenti, Laura Z., Zhang, Cathy, Liu, Shu-Hui, Smeal, Tod, Fantin, Valeria R., Kipps, Thomas J., Pernasetti, Flavia, Castro, Januario E.
Publicado 2017